Results 141 to 150 of about 118,032 (300)

Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer [PDF]

, 2002
John S. Oghalai, K Shay, T Yoneyama, M Yoshida, T Ohrui, C Wyatt, H Frenkel, I Harvey, R Newcombe, D Simons, E Kidd, D Beighton   +11 more
openalex   +1 more source

ERM Inhibition Confers Ferroptosis Resistance through ROS‐Induced NRF2 Signaling

Advanced Science, EarlyView.
ERM inhibition disrupts ERM‐actin interactions, elevating ROS and triggering KEAP1 degradation, which stabilizes and activates NRF2. Nuclear NRF2 induces cytoprotective genes, notably HMOX1, enhancing redox buffering and suppressing lipid peroxidation to resist erastin‐induced ferroptosis.
Menghao Qiao, Liqun Zhou, Minhua Zhou, Yu Fang, Haiying Mai, Lingbo Cao, Kun Xu, Yuan Sang, Minyi Chen, Jiewei Huang, Peiyi Huang, Zhipeng Yan, Chao Wang, Zhangshuai Dai, Dichun Huang, Ronghan He, Lijuan Pang, Yunmiao Guo, Ting Gang Chew, Junqi Huang   +19 more
wiley   +1 more source

Comparative Effects of Hormone Replacement Therapy and Exercise on Bone Health in Postmenopausal Women: A Systematic Review. [PDF]

Cureus
Treviño M, Leiker P, Palnati SR, Bhakta S.   +3 more
europepmc   +1 more source

One effect and two causes: Growth acceleration and breast cancer risk after hormone replacement therapy [PDF]

D. Hölzel, Anne Schlesinger‐Raab, Kathrin Halfter   +2 more
openalex   +1 more source

Astrocytic PCBP1 Suppresses Ferroptosis to Restore Glutamatergic Homeostasis and Mitigate Stress‐Induced Depression in Male Mice

Advanced Science, EarlyView.
This study demonstrates that polyC‐RNA‐binding protein 1 (PCBP1) in ventral hippocampal astrocytes modulates depressive‐like behaviors by regulating glutathione peroxidase 4‐mediated ferroptosis and synaptic glutamatergic transmission. PCBP1 overexpression intervention in the chronic unpredictable mild stress model rescues behavioral deficits ...
Jinyu Zhang, Binbin Zhao, Min Jia, Yan Zhao, Ye Lu, Wenyu Xi, Ziyu Zhu, Xiaojuan Gong, Qingyan Ma, Yuan Gao, Yijie Guo, Pan Li, Feng Zhu, Shuguang Wei, Xiancang Ma, Yunpeng Wang   +15 more
wiley   +1 more source

Hormone replacement therapy.

Biomedicine & Pharmacotherapy, 2000
Anne Johanne Søgaard, Anne Tollan, Gro K.R Berntsen, Vinjar Fønnebø, Jeanette H Magnus   +4 more
  +4 more sources

HSP70 Interactome‐Mediated Proteolysis Targeting Chimera (HSP70‐PROTAC) for Ferroptosis‐Driven Cancer Treatment

Advanced Science, EarlyView.
This study reports a novel targeted protein degradation strategy termed “HSP70‐PROTAC” that recruits Hsc70 complex to a target protein for inducing degradation. Among them, GDAz‐3 exhibits effective GPX4 degradation activity via UPS/CMA processes, triggering ferroptosis‐driven anticancer activity in vitro and in vivo.
Jinyun Dong, Yulong Li, Hui Liang, Zumei Wu, Shiqun Wang, Yichao Wang, Jieyu Xu, Yanning Lan, Maohua Cai, Guangzhao Pan, Haiyan Yang, Kai Miao, Zhe‐Sheng Chen, Fangfang Tao, Xuelei Ma, Jiang‐Jiang Qin   +15 more
wiley   +1 more source

Awareness of Menopause and Hormone Replacement Therapy Among Women in a Tertiary Care Hospital in Tamil Nadu. [PDF]

Cureus
G A, Sr V, T S M, Lakshmi G.
europepmc   +1 more source

Menopause and hormone-replacement therapy: Part 2. Hormone-replacement therapy regimens

Western Journal of Medicine, 2001
S, Ratner, D, Ofri
openaire   +3 more sources

Combined Photothermal and mTOR‐Targeted Therapy Overcomes Immune Evasion and Enhances Checkpoint Blockade Efficacy in Metastatic Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
This study reveals that photothermal therapy, while inducing immunogenic cell death in triple‐negative breast cancer, paradoxically activates the oncogenic mTOR pathway to drive immune evasion. To counter this, a smart nanocomposite is engineered to co‐deliver localized hyperthermia and mTOR inhibition.
Yujie Zhao, Jing Yu, Xin Wang, Xu Liu, Fengli Zuo, Tianyue Xu, Leyi Tang, Ling Xiong, Li Li, Huifang Li, Xiaoting Chen, Guang Yang, Jing Jing, Xiaowei Liu   +13 more
wiley   +1 more source